Oxford BioMedica (OTCMKTS:OXBDF) Stock Price Up 15% – Should You Buy?

Shares of Oxford BioMedica (OTCMKTS:OXBDF) shot up 15% during mid-day trading on Tuesday. The company traded as high as $7.65 and last traded at $7.65. 100 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 5,962 shares. The stock had previously closed at $6.65.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded Oxford BioMedica to a “hold” rating in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the company currently has an average rating of “Hold”.

Oxford BioMedica Stock Performance

The firm’s 50-day simple moving average is $6.93 and its 200-day simple moving average is $7.66.

Oxford BioMedica Company Profile

Oxford BioMedica plc is a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The company works with biotechnology and pharmaceutical customers to develop, manufacture and test viral vectors and other biological materials used in advanced therapies.

Its capabilities include process and analytical development, clinical and commercial manufacturing, quality control, regulatory support and technology transfer. Oxford BioMedica has particular expertise in lentiviral vectors, which are used to deliver genetic material into cells, and also provides services involving adeno-associated virus and other viral-vector platforms.

Founded in 1995 and headquartered in Oxford, England, the company serves customers internationally across the pharmaceutical and biotechnology industries.